HHealthcare Read More You Want To Join a Clinical Trial. Here’s What To Know About the Hurdles.August 20, 2026 Connecting people with clinical trials is complicated — even if people identify a promising match, there’s a slew…
MMedication Read More Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical studyJuly 28, 2026 Adult B-ALL exhibits significant heterogeneity and poor prognosis compared with the pediatric population. While the complete remission (CR)…
HHealth Read More Newly Identified Inhibitors May Boost Chemotherapy Drug’s Ability to Fight Treatment-Resistant CancersJuly 15, 2026 Newswise — In a new report of research, scientists at Johns Hopkins University School of Medicine and Johns…
HHealthcare Read More TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant SchizophreniaJuly 7, 2026 TG Therapeutics, Inc. Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60…
HHealthcare Read More 3 Companies Redefining Healthcare InnovationJune 25, 2026 This article was originally published on ETFTrends.com. The Healthcare Technology and Innovation index (HTEC) was launched back in…
MMental health Read More Definium LSD therapy for major depression helped patients in Phase 3 trialJune 24, 2026 Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
MMedication Read More Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with TacrolimusJune 22, 2026 Eledon Pharmaceuticals, Inc. Tegoprubart-treated patients maintained higher mean eGFR over time, including a statistically significant approximately 12 mL/min/1.73…
HHealthcare Read More TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 TrialJune 10, 2026 TG Therapeutics, Inc. 82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement…
NNutrition Read More The Supplement That Science Says Could Make the World Less AngryJune 5, 2026 If you found out a supplement existed that could lower aggression, you would probably think it was something…
NNutrition Read More The Supplement That Science Says Could Make the World Less AngryMay 29, 2026 If you found out a supplement existed that could lower aggression, you would probably think it was something…
NNutrition Read More Industry and regulators signal a smarter, collaborative era for supplement oversightMay 27, 2026 While the industry has spent years bracing for and fending off a heavier regulatory hand, what it heard…
HHealth Read More Researcher harnesses gut bacteria for new therapiesMay 19, 2026 Inside the human gut lives a hidden world of trillions of microbes – and Professor Sam Forster is…